And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. And our agenda is ambitious. We hope to noodle around the Pharmalot grounds, visit the Pharmalot ancestors and take in another installment of our ‘Let’s-see-them-before-they-die‘ concert series. And what about you? This is, as we regularly remind you, a fine time to enjoy the great outdoors. Perhaps, you could catch up on your reading or make time for someone special. Or you could tune out the real world and watch the Royal Wedding. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon…

Amgen (AMGN) will charge $6,900 a year for a new drug that can spare migraine sufferers a few headaches each month, a price well below Wall Street expectations as the company hopes to avoid payer backlash that has hamstrung recent drug launches, STAT reports. The drug, called Aimovig, is meant for patients who experience at least four migraines per month. There are roughly 24 million patients in the U.S. who would be candidates for treatment. The Institute for Clinical and Economic R, a nonprofit that assesses the value of medicines, pegged cost effectiveness at $8,500.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy